Cidara Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cidara Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Cidara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $751K, a 5.65% decline year-over-year.
  • Cidara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $3.08M, a 6.03% increase year-over-year.
  • Cidara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3.06M, a 17.4% decline from 2022.
  • Cidara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.71M, a 7.7% decline from 2021.
  • Cidara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $4.01M, a 1.86% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $3.06M -$644K -17.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-04-22
2022 $3.71M -$309K -7.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-04-22
2021 $4.01M -$76K -1.86% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 $4.09M -$983K -19.4% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-23
2019 $5.07M -$637K -11.2% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-07
2018 $5.71M -$4K -0.07% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $5.71M +$1.37M +31.5% Jan 1, 2017 Dec 31, 2017 10-K 2019-02-28
2016 $4.34M +$1.31M +43.2% Jan 1, 2016 Dec 31, 2016 10-K 2018-02-27
2015 $3.03M +$2.8M +1207% Jan 1, 2015 Dec 31, 2015 10-K 2017-03-15
2014 $232K Jan 1, 2014 Dec 31, 2014 10-K 2016-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.